NLS Pharmaceutics Teams Up with Kadimastem and TargetGene for Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Collaboration Announcement: NLS Pharmaceutics and Kadimastem have signed a Memorandum of Understanding with TargetGene Biotechnologies to combine their expertise in cell therapy and gene-editing technologies.
Joint Development Goals: The collaboration aims to develop and optimize gene-edited cell therapy products, focusing on specific genome modifications with minimal off-target effects.
Future Company Structure: The partnership will continue under the new entity, NewCelX, following the anticipated merger between NLS and Kadimastem.
Framework for Innovation: The MOU establishes a framework for joint research and development activities, technology exchange, and potential licensing opportunities between the companies.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
